@article{bibcite_8861,
  keywords = {Cancer genomics, Cancer models},
  author = {Dina ElHarouni and Mushriq Al-Jazrawe and Seongmin Choi and Merve Dede and Toshinori Hinoue and Sean A. Misek and Heeju Noh and Luca Zanella and Yuen-Yi Tseng and Hayley E. Francies and Dennis Plenker and Cindy W. Kyi and Julyann Perez-Mayoral and Megan J. Stine and Eva Tonsing-Carter and Rachana Agarwal and Jean Claude Zenklusen and James M. Clinton and Jennifer M. Shelton and Timothy R. Chu and William F. Hooper and Xavi Loinaz and Paula Keskula and Jordan Tagle and Peyton C. Kuhlers and Bahar Tercan and Sylvia F. Boj and Alessandro Vasciaveo and Lorenzo Tomassoni and James M. Crawford and Shawna Walsh and Claire Sinai and Sonam Bhatia and Priya Sridevi and Hardik Patel and Maria Antonietta Cerone and Kyle Ellrott and Calvin J. Kuo and Olivier Elemento and Semir Beyaz and Vincenzo Corbo and David L. Spector and Rameen Beroukhim and Martin L. Ferguson and Andrew D. Cherniack and Peter W. Laird and Nicolas Robine and Andrew McPherson and Katherine A. Hoadley and Mathew J. Garnett and David A. Tuveson and Andrea Califano and Paul T. Spellman and Keith L. Ligon and Daniela S. Gerhard and Louis M. Staudt and Jesse S. Boehm},
  title = {A compendium of next-generation patient-derived models for diverse cancers},
  abstract = {The development of new therapeutics and the validation of pathogenetic cancer mechanisms require representative laboratory models1,2. However, existing collections represent only a fraction of the diversity observed in human cancer2{\textendash}4. Recent technologies have enabled efficient in vitro model derivation (for example, tumour organoids)5. However, whether these maintain essential properties of patient tumours during long-term expansion has not been systematically investigated. Here we present results of a large-scale international programme{\textemdash}the Human Cancer Models Initiative{\textemdash}which involved the generation of a resource of 665 next-generation models from 2,780 donors with 25 cancer types and integrated tumour{\textendash}model whole genome, exome, methylome and transcriptome analyses. The resource provides 522 models with comprehensive clinical data, 153 models of rare cancers and 71 models from participants with non-European ancestry. Analyses of 421 matched tumour{\textendash}model pairs reveal high genetic (97.8\%) and epigenetic (95\%) concordance and define correlates of model discordance. Single-nucleus RNA sequencing of tumour{\textendash}model pairs reveals subsets of models in which culture conditions significantly influence cell states. Finally, we characterize model preservation of extrachromosomal DNA and post-treatment mutational signatures to provide opportunities to study therapeutic resistance. This model repository is being made available to the community{\textemdash}including multimodal molecular profiling, clinical information and integrative software tools{\textemdash}thus providing a valuable resource for preclinical investigation of cancer pathogenesis and treatment response.},
  year = {2026},
  journal = {Nature},
  pages = {1-14},
  month = {2026-08-05},
  issn = {1476-4687},
  url = {https://www.nature.com/articles/s41586-026-10806-y},
  doi = {10.1038/s41586-026-10806-y},
  language = {en},
}